AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9756471 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (IFN) therapy at a daily dose of 5 million international units
Number of subjects: 23
Study 9756471 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (IFN) therapy at a daily dose of 10 million international units
Number of subjects: 23
Study 9756471 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (IFN) therapy at a daily dose of 15 million international units
Number of subjects: 23
Study 9756471 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (IFN) therapy
Number of subjects: 23
Study 8167575 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Care Unit (SCU)
Number of subjects: 22
Study 8167575 — intervention group
Group type: COMPARATOR
Intervention: Traditional integrated units
Number of subjects: 22
Study 3168620 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium intervention
Number of subjects: 10
Study 3168620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intervention
Number of subjects: 10
Study 3168620 — intervention group
Group type: EXPERIMENTAL
Intervention: High intervention
Number of subjects: 10
Study 3168620 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 10
Study 12185890 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31876197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone supplementation (30 mg/d)
Number of subjects: 406
Study 30178335 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 12
Study 30178335 — intervention group
Group type: COMPARATOR
Intervention: Upright position
Number of subjects: 12
Study 27339759 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 946
Study 27339759 — intervention group
Group type: COMPARATOR
Intervention: COC
Number of subjects: 946
Study 25434316 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (sugarless gum, half an hour three times daily after meals for 3 days)
Number of subjects: 129
Study 25434316 — intervention group
Group type: COMPARATOR
Intervention: High-dose senna (150 mL senna solution, 300 mg senna the night before colonoscopy and 80 mg sennoside tablet daily for 3 days)
Number of subjects: 129
Study 22392169 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed breast milk (EBM)
Number of subjects: 113
Study 22392169 — intervention group
Group type: COMPARATOR
Intervention: 25% glucose (control group)
Number of subjects: 113
Study 20938039 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg aspirin daily for 12 weeks
Number of subjects: 70
Study 20938039 — intervention group
Group type: EXPERIMENTAL
Intervention: 162.5 mg aspirin daily for 12 weeks
Number of subjects: 70
Study 20938039 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg aspirin daily for 12 weeks
Number of subjects: 70
Study 20938039 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg aspirin daily for 12 weeks
Number of subjects: 70
Study 20938039 — intervention group
Group type: EXPERIMENTAL
Intervention: 1300 mg aspirin daily for 12 weeks
Number of subjects: 70
Study 18726812 — intervention group
Group type: EXPERIMENTAL
Intervention: MyStudentBody-Stress
Number of subjects: 0
Study 18726812 — intervention group
Group type: COMPARATOR
Intervention: Control health information website
Number of subjects: 0
Study 18726812 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 15613583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 15613583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12402052 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel hemorrhoidectomy (HS)
Number of subjects: 54
Study 12402052 — intervention group
Group type: COMPARATOR
Intervention: Milligan‐Morgan procedure (MM)
Number of subjects: 54
Study 10433671 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate
Number of subjects: 5
Study 10433671 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain liquid soap
Number of subjects: 5
Study 10433671 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine
Number of subjects: 5
Study 10433671 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% ethyl alcohol
Number of subjects: 5
Study 7607751 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ramipril and enalapril)
Number of subjects: 7
Study 2222157 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual stretch of extrinsic finger flexor muscles
Number of subjects: 16
Study 2222157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no manual stretch)
Number of subjects: 16
Study 2222157 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (manual stretch)
Number of subjects: 16
Study 364010 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride solution and/or silver nitrate treatment
Number of subjects: 0
Study 364010 — intervention group
Group type: COMPARATOR
Intervention: No treatment or placebo
Number of subjects: 0
Study 31130215 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning models (ANN, SVM, Naïve Bayes) using computed IVUS features
Number of subjects: 517
Study 31130215 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning models (ANN, Naïve Bayes) in the test set
Number of subjects: 517
Study 31130215 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS sections with OCT-TCFA
Number of subjects: 517
Study 31130215 — intervention group
Group type: COMPARATOR
Intervention: IVUS sections without OCT-TCFA
Number of subjects: 517
Study 28767333 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session version of GPM augmented with MOTR
Number of subjects: 50
Study 28767333 — intervention group
Group type: COMPARATOR
Intervention: 10-session version of GPM (control group)
Number of subjects: 50
Study 25266357 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training + pelvic floor muscle training (BT + PFMT)
Number of subjects: 108
Study 25266357 — intervention group
Group type: COMPARATOR
Intervention: Bladder training (BT)
Number of subjects: 108
Study 23812136 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative bowel preparation (group A)
Number of subjects: 60
Study 23812136 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation (group B)
Number of subjects: 60
Study 20523301 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diet for 12 weeks
Number of subjects: 78
Study 19548447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ganji recipe and Fructus Bruceae oil emulsion (FBE)
Number of subjects: 77
Study 19548447 — intervention group
Group type: COMPARATOR
Intervention: Trans‐hepatic arterial chemical embolization (TACE) alone
Number of subjects: 77
Study 19548447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ganji recipe and FBE
Number of subjects: 77
Study 19548447 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 77
Study 16910066 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 grams of second generation cephalosporin (cefuroxime sodium) diluted in 100ml of normal saline at the time of induction of anesthesia (Group A)
Number of subjects: 93
Study 16910066 — intervention group
Group type: COMPARATOR
Intervention: Normal saline only (Group B)
Number of subjects: 93
Study 12765457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual chamber pacing
Number of subjects: 6000
Study 12765457 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial-based pacing
Number of subjects: 6000
Study 10639031 — intervention group
Group type: EXPERIMENTAL
Intervention: BR21 (0.5, 1.0, 1.5, 2.0, and 2.5 mL/kg)
Number of subjects: 30
Study 10639031 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline, 10 volunteers)
Number of subjects: 30
Study 10639031 — intervention group
Group type: EXPERIMENTAL
Intervention: BR21
Number of subjects: 30
Study 8940985 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion
Number of subjects: 24
Study 8940985 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 24
Study 8940985 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation
Number of subjects: 24
Study 8940985 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for metabolic acidosis
Number of subjects: 24
Study 8940985 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid replacement
Number of subjects: 24
Study 1537519 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg chenodeoxycholic acid (CDCA)
Number of subjects: 6
Study 1537519 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg UDCA
Number of subjects: 6
Study 1537519 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg UDCA
Number of subjects: 6
Study 1537519 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg UDCA
Number of subjects: 6
Study 1537519 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg UDCA
Number of subjects: 6
Study 1537519 — intervention group
Group type: COMPARATOR
Intervention: Control period (no UDCA administration)
Number of subjects: 6
Study 6375710 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet of pindolol 10 mg and clopamide 5 mg
Number of subjects: 160
Study 6375710 — intervention group
Group type: COMPARATOR
Intervention: Separate tablets of pindolol 10 mg and clopamide 5 mg
Number of subjects: 160
Study 31165854 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 0
Study 31165854 — intervention group
Group type: COMPARATOR
Intervention: Chemo-endocrine therapy
Number of subjects: 0
Study 31165854 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncotype DX testing
Number of subjects: 0
Study 31165854 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy use
Number of subjects: 0
Study 31165854 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial care costs posttrial
Number of subjects: 0
Study 31165854 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for women aged 50 years and younger with RS 16-25
Number of subjects: 0
Study 29141505 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet with zinc supplements (GFD +Zn)
Number of subjects: 71
Study 29141505 — intervention group
Group type: COMPARATOR
Intervention: Gluten-free diet (GFD)
Number of subjects: 71
Study 27621440 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment that framed healthy eating as consistent with adolescent values of autonomy and social justice
Number of subjects: 536
Study 27621440 — intervention group
Group type: COMPARATOR
Intervention: Traditional health education materials
Number of subjects: 536
Study 27621440 — intervention group
Group type: COMPARATOR
Intervention: Non-food-related control
Number of subjects: 536
Study 27621440 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment that framed healthy eating as consistent with adolescent values
Number of subjects: 536
Study 23721647 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus ω‐3 supplementation (EPA + DHA, 3 g/d)
Number of subjects: 10
Study 23721647 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing plus placebo
Number of subjects: 10
Study 22776871 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen twice before cycling
Number of subjects: 9
Study 22776871 — intervention group
Group type: COMPARATOR
Intervention: Cycling without ibuprofen
Number of subjects: 9
Study 22776871 — intervention group
Group type: COMPARATOR
Intervention: 400 mg ibuprofen twice at rest
Number of subjects: 9
Study 22776871 — intervention group
Group type: COMPARATOR
Intervention: Rest without ibuprofen intake
Number of subjects: 9
Study 22776871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling with ibuprofen
Number of subjects: 9
Study 22776871 — intervention group
Group type: COMPARATOR
Intervention: 400 mg ibuprofen at rest
Number of subjects: 9
Study 22776871 — intervention group
Group type: COMPARATOR
Intervention: Rest without ibuprofen
Number of subjects: 9
Study 21046504 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 174
Study 21046504 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 174
Study 17609332 — intervention group
Group type: COMPARATOR
Intervention: Random practice order in control group
Number of subjects: 40
Study 17609332 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice order in control group
Number of subjects: 40
Study 17609332 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice order in PD group
Number of subjects: 40
Study 17609332 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice order in PD group
Number of subjects: 40
Study 15625158 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine 75 mg daily for 12 weeks
Number of subjects: 80
Study 15625158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12119210 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based education program (8 classes in 1 year)
Number of subjects: 104
Study 12119210 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based education program
Number of subjects: 104
Study 12119210 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 classes)
Number of subjects: 104
Study 9710040 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I 0.1 mg/kg/day subcutaneously for 9 months
Number of subjects: 183
Study 9710040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 7480965 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (2 mg orally)
Number of subjects: 18
Study 7480965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7480965 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 18
Study 2470569 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng/kg.min over six hours for 28 consecutive days)
Number of subjects: 101
Study 2470569 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion for 28 consecutive days)
Number of subjects: 101
Study 53719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular insulin (small doses)
Number of subjects: 36
Study 53719 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of insulin (small doses)
Number of subjects: 36
Study 53719 — intervention group
Group type: COMPARATOR
Intervention: Large intravenous boluses of insulin (control)
Number of subjects: 36
Study 53719 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium requirements during treatment (both groups)
Number of subjects: 36
Study 30868497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular parecoxib (40 mg)
Number of subjects: 101
Study 30868497 — intervention group
Group type: COMPARATOR
Intervention: 1% tetracaine gel (control group)
Number of subjects: 101
Study 28957887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-propofol-midazolam (KPM)
Number of subjects: 80
Study 28957887 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-propofol-midazolam (FPM)
Number of subjects: 80
Study 23689964 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic transtendon repair
Number of subjects: 74
Study 23689964 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic completion of the tear and formal repair
Number of subjects: 74
Study 25111121 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (SUC) or high fructose corn syrup (HFCS) in low-fat milk at 8%, 18% or 30% of calories
Number of subjects: 355
Study 22981146 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 to 80 mg for 42 days (dyslipidemic patients)
Number of subjects: 26
Study 22981146 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg for 21 days (non-patient volunteers)
Number of subjects: 26
Study 18971794 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol gel 0.1% (1.0 mg/day)
Number of subjects: 488
Study 18971794 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol gel 0.1% (0.5 mg/day)
Number of subjects: 488
Study 18971794 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol gel 0.1% (0.25 mg/day)
Number of subjects: 488
Study 18971794 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol gel 0.1% (1.0, 0.5, and 0.25 mg/day)
Number of subjects: 488
Study 18971794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 488
Study 17825656 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective cesarean delivery
Number of subjects: 0
Study 14762749 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire osteosynthesis and maxillomandibular fixation for 6 weeks (Group 1)
Number of subjects: 37
Study 14762749 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid internal fixation (Group 2)
Number of subjects: 37
Study 14762749 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 37
Study 11133633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg IV before spinal anesthesia
Number of subjects: 60
Study 11133633 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study 9625823 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNA labeling index in lung metastasis group
Number of subjects: 26
Study 9625823 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNA labeling index in primary lesions of lung metastasis group
Number of subjects: 26
Study 9625823 — intervention group
Group type: COMPARATOR
Intervention: PCNA labeling index in no metastasis group
Number of subjects: 26
Study 9625823 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA distribution patterns
Number of subjects: 26
Study 9625823 — intervention group
Group type: EXPERIMENTAL
Intervention: CA19-9 staining patterns
Number of subjects: 26
Study 8143396 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 18
Study 8143396 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac
Number of subjects: 18
Study 8143396 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin and Etodolac
Number of subjects: 18
Study 3144441 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil (15 micrograms.kg‐1)
Number of subjects: 59
Study 3144441 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl (1.5 microgram.kg‐1)
Number of subjects: 59
Study 3144441 — intervention group
Group type: EXPERIMENTAL
Intervention: enflurane
Number of subjects: 59
Study 2147834 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (3.6 mg/kg total dose over 3 hours)
Number of subjects: 20
Study 2147834 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (10 micrograms/kg/min for 30 minutes)
Number of subjects: 20
Study 2147834 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 20
Study 2147834 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 20
Study 1097343 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0
Study 1097343 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 0
Study 1097343 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline or Minocycline
Number of subjects: 0
Study 31558359 — intervention group
Group type: EXPERIMENTAL
Intervention: High dynamic sports
Number of subjects: 37
Study 31558359 — intervention group
Group type: EXPERIMENTAL
Intervention: High dynamic and static sports
Number of subjects: 37
Study 31558359 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial metabolites (faecal) and human metabolites (urine)
Number of subjects: 37
Study 31558359 — intervention group
Group type: COMPARATOR
Intervention: Dietary intake
Number of subjects: 37
Study 30151651 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision-Making using Routine Outcome Monitoring (SDMR)
Number of subjects: 186
Study 30151651 — intervention group
Group type: COMPARATOR
Intervention: Decision-Making As Usual (DMAU)
Number of subjects: 186
Study 28706331 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded amoxicillin capsule
Number of subjects: 12
Study 28706331 — intervention group
Group type: COMPARATOR
Intervention: Generic amoxicillin capsule
Number of subjects: 12
Study 24965202 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 0
Study 24965202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23986090 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib 150 mg daily (monotherapy)
Number of subjects: 231
Study 23986090 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg during 15 days intercalated with four 21-day cycles of docetaxel or pemetrexed (combination therapy)
Number of subjects: 231
Study 20659263 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole plus vitamin B12
Number of subjects: 147
Study 20659263 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 only
Number of subjects: 147
Study 20659263 — intervention group
Group type: COMPARATOR
Intervention: Levamisole only
Number of subjects: 147
Study 20659263 — intervention group
Group type: COMPARATOR
Intervention: No further vitamin B12 treatment
Number of subjects: 147
Study 19746240 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (up to 8 mg/day)
Number of subjects: 0
Study 19746240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18193690 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 8 mg sore throat lozenges
Number of subjects: 240
Study 18193690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 15175564 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg daily)
Number of subjects: 20
Study 15175564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11461055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oarsmen
Number of subjects: 39
Study 9515666 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem 3 x 1.0 g per day
Number of subjects: 192
Study 9515666 — intervention group
Group type: COMPARATOR
Intervention: Imipenem 3 x 0.5 g per day
Number of subjects: 192
Study 9515666 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 192
Study 7829275 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-oriented program
Number of subjects: 0
Study 7829275 — intervention group
Group type: COMPARATOR
Intervention: Indefinite methadone maintenance
Number of subjects: 0